1 / 19

Class Exercise on GlaxoSmithKline

Class Exercise on GlaxoSmithKline. Agenda. External Environment. Competitive Advantage. GSK Overview - Fundamentals and business mix - Stock brokers assessments Industry Drivers - Changes in industry structure - Future Trends Problems and risks (backup) Recommendations

alesia
Télécharger la présentation

Class Exercise on GlaxoSmithKline

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Class Exercise on GlaxoSmithKline

  2. Agenda External Environment Competitive Advantage • GSK Overview - Fundamentals and business mix - Stock brokers assessments • Industry Drivers - Changes in industry structure - Future Trends • Problems and risks (backup) • Recommendations - New approach to marketing and others - Follow on activity - Financial perspectives Finance Value Based Management Strategy

  3. Fundamentals and Business Mix Business Segment & Geographic Revenue Mix By Business Segments By Region Europe Consumer Health 30% 14% International 22% Pharma US 48% 86%

  4. Challenges – Stock Broker’s Assessment • Negative outlook of Avandia (10% decline in sales per year) • Few upside catalysts • Possibility of withdrawal from the market • Strong pipeline: phase II and phase III • Marketing: recent restructuring for marketing team • Share buyback (?)

  5. Avandia (6%) of the total • Seretide/Advair £3,313 million 11% • Zofran £847 million, up 3% • Vaccines products £1,692 million, up 23% • Valtrex £845 million, up 24% • Avandia group of products £1,645 million, up 25% • Coreg £779 million, up 38% • Lamictal £996 million, up 19% • Imigran/Imitrex £711 million, up 3% • Wellbutrin £900 million, up 24% • Flixotide/Flovent £659 million, up 5%

  6. Comparison Highest RoE among peers

  7. Industry Drivers • Product in the Pipeline • Marketing: Moving strength to strength • Regulations: tighter controls and tougher business environment (FDA in USA) • Increasing number of generic claims • Declining number of approvals • Shorter lifetime for ethical drugs • Increase in M&A : winner or loser • Globalization

  8. Socio economic impacts (Macro factors) - Change in population and age structure (10% of 08 - 40% of 50) - Increase of medical PMT in GDP (OECD 8.5%) Impact and fusion from High Technology in IT, LS and NT Innovative products and equipment - Electronic pills - Cutting edge equipment for surgery - Synthetic body Replacement Advent of QOL (quality of life) products - election, obesity, hair treatment, etc. Stem cell research : paradigm change in medical treatment IT Pharmaceutical Industry NT LS New Trends in Pharma

  9. Recent M&A between Pharmas and Bios

  10. Pharmaceutical Companies in past decade: A Clear Divide of Winner & Loser Competitive Market Environment Accelerating overseas operation Improvement the efficiency of operations 積極的な海外展開 経営効率化 Change in Business structure Profit Sustainable Growth Concentrated investment on R&D 研究開発への 重点投資 Performance Gap Innovation 業績格差

  11. Recommendation : Approach by the IncomingCEO • Positioning : ‘Front Runner in the global Health Care industry’ • Securing Strong Next Growth Engines • M&A and Strategic Partnership : new technology - Pipeline (patents) management : R&D outsourcing • Emphasizing on the emerging markets (China and India) • New market strategy and branding • Developing the vaccine market as major target • B2B Value added community • Creation on life time value to customers • Set-up Vision with stakeholders : ’The Most Admired Company in Ethical Market by 2010’

  12. Positioning in Strategic Map H Group D F6 Group C F 7 F5 Group B Pharmaceutical GSK F3 Barrier of movement F4 Group A • Economy of Scale • High Technology • Marketing / Brand • Corporate Reputation F 8 Group F F1 F2 L L H Bio Technology

  13. Financial Perspectives in 2010 Gaining market efficiencies through the B2B network • Reduced marketing costs • Restructuring R&D and new market potential • Enhanced supply chain management • Supply side : mix optimal supply with long-term relationship • Demand sides : direct link and extra growth margin Utilizing New Pipelines (patents) : 20% upward in sales Operational Efficiency by BPR : 5% (Globally)

  14. Thank you

  15. Ways to Create B2B VAC • Buying Power : price discount by scale, providing detailed information on suppliers and manufactures • Increasing Process Efficiency : cost savings by transaction, and work process • Consolidation of Supply Chains : process consolidation, logistics improvement, inventory reduction, no mediate process • Accumulation Contents and Community : best practice, KMS, VM, forum, news letter • Efficiency of Market Research : e-catalogue, auction, exchange, bidding (cyber-market usage)

  16. Value Added Communities Supplier Buyer B2B Platform Supplier Buyer Supplier Buyer VAC (Value Added Communities)

  17. Investment in World Health

  18. Problems and Risks • Possibility of late stage trial failures • Expiration of patented drugs (pipelines) :$13B in 10 yr • Lack of next Growth engine : M&A $2B over 02-06 • Corporate ethics : - Rejection of benefits package for CEO (Fat Cat) - Customer of animal testing companies (FETA) - Short-term monopoly profit anti-AIDS drug AZT - Avandia issue: Case pending • Competition from generic drugs and quick • Change in the industry structure • The New Chairman • Debunking : from the stories to the global capital market (abundant liquidity)

  19. Major development – Potential Revenue Major NCEs and vaccines filed: • Allermist/Avamys – for hay fever; US approval expected in first half of 2007 • Altabax/Altargo – for skin infections; approval expected in 2007 • Entereg – for post-operative ileus, approval expected in 2007 • Tykerb – for breast cancer; US approval expected in first half of 2007 • Cervarix – vaccine to prevent cervical cancer; European and International launches expected in second half of 2007 • H5N1 pandemic vaccine. Late-stage assets in-licensed during the last 12 months: • Hu-Max-CD20 – for the treatment of leukaemia and non-Hodgkin’s lymphoma • gepirone ER – for major depressive disorder • XP13512 – for restless legs syndrome and treatment of neuropathic pain. Major NCEs and vaccines in phase III development: ambrisentan – for hypertension Lymphostat-B* – for lupus casopitant* – for post-operative and chemotherapy-induced vomiting and nausea pazopanib* – for prevention of tumour growth mepolizumab – for hypereosinophilic syndrome Promacta* – for patients with low platelet count New generation ‘flu vaccine* • Globorix – a new combination paediatric vaccine against hepatitis B, diphtheria, meningitis A and C • New meningitis vaccine against meningitis C and Y and Hib* • Synflorix – vaccine to prevent pneumococcal disease. (* entered late-stage in the last 12 months)

More Related